Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | QPCT | Q16769 | 2/20 | 0.47 |
| ▸ | CETP | P11597 | 4/20 | 0.42 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.40 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.40 |
| ▸ | APP | P05067 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | SLC2A4 | P14672 | 3/20 | 0.38 |
| ▸ | SLC2A8 | Q9NY64 | 1/20 | 0.38 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.38 |
| ▸ | CAMKK2 | Q96RR4 | 1/20 | 0.38 |
| ▸ | SLC2A1 | P11166 | 3/20 | 0.38 |
| ▸ | BCHE | P06276 | 1/20 | 0.37 |
| ▸ | ACHE | P22303 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29194586 | 0.99 | QPCT (0.47) | QPCTCETPMTNR1AMTNR1BAPP | |
| SCHEMBL30245279 | 0.99 | QPCT (0.47) | QPCTCETPMTNR1AMTNR1BAPP | |
| SCHEMBL30245420 | 0.94 | QPCT (0.44) | QPCTCETPPOLBHPGDRECQL | |
| SCHEMBL30245310 | 0.90 | QPCT (0.53) | QPCTCETPMTNR1AMTNR1BAPP | |
| SCHEMBL25295796 | 0.89 | QPCT (0.39) | QPCTCETP | |
| SCHEMBL30245196 | 0.89 | QPCT (0.39) | QPCTCETP | |
| SCHEMBL30244877 | 0.89 | QPCT (0.49) | QPCTCETPSLC2A4SLC2A8SLC2A1 | |
| SCHEMBL30245693 | 0.89 | QPCT (0.52) | QPCTCETPMTNR1AMTNR1BAPP | |
| SCHEMBL25426407 | 0.88 | QPCT (0.64) | QPCTPOLBHPGDRECQL | |
| SCHEMBL30245326 | 0.88 | QPCT (0.64) | QPCTPOLBHPGDRECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240360113-A1 | AMINOARYL-INTEGRIN AGONISTS COMPOUNDS | TEXAS HEART INSTITUTE (US) | 2024-10-31 | — | — | US | claimed |
| EP-4384516-A1 | AMINOARYL-INTEGRIN AGONISTS COMPOUNDS | Texas Heart Institute (US) | 2024-06-19 | — | — | EP | claimed |
| CN-117916237-A | Amino aryl integrin agonist compounds | 德克萨斯心脏研究所 | 2024-04-19 | — | — | CN | claimed |
| WO-2023018472-A9 | AMINOARYL-INTEGRIN AGONISTS COMPOUNDS | TEXAS HEART INSTITUTE (US) | 2023-07-13 | — | — | WO | claimed |
| WO-2023018472-A1 | AMINOARYL-INTEGRIN AGONISTS COMPOUNDS | TEXAS HEART INSTITUTE (US) | 2023-02-16 | — | — | WO | claimed |
| US-20240360113-A1 | AMINOARYL-INTEGRIN AGONISTS COMPOUNDS | TEXAS HEART INSTITUTE (US) | 2024-10-31 | — | — | US | disclosed |
| EP-4384516-A1 | AMINOARYL-INTEGRIN AGONISTS COMPOUNDS | Texas Heart Institute (US) | 2024-06-19 | — | — | EP | disclosed |
| CN-117916237-A | Amino aryl integrin agonist compounds | 德克萨斯心脏研究所 | 2024-04-19 | — | — | CN | disclosed |
| WO-2023018472-A9 | AMINOARYL-INTEGRIN AGONISTS COMPOUNDS | TEXAS HEART INSTITUTE (US) | 2023-07-13 | — | — | WO | disclosed |
| WO-2023018472-A1 | AMINOARYL-INTEGRIN AGONISTS COMPOUNDS | TEXAS HEART INSTITUTE (US) | 2023-02-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240360113-A1 | AMINOARYL-INTEGRIN AGONISTS COMPOUNDS | ITGB3, ITGA2, ITGAV | QPCT 4258/4885CETP 4377/4885MTNR1A 610/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.